Loading clinical trials...
Loading clinical trials...
Impact of Body Composition on the Prognosis and Toxicity of Patients Diagnosed With Recurrence or Metastasic Squamous Cell Carcinoma of the Head and Neck (SCCHN) Treated With Immune Checkpoint Inhibitors (ICI)
Conditions
Locations
1
Spain
Institut Catala d'Oncologia
L'Hospitalet de Llobregat, Barcelona, Spain
Start Date
January 20, 2021
Primary Completion Date
November 1, 2023
Completion Date
August 1, 2024
Last Updated
January 22, 2021
NCT05884138
NCT06950125
NCT07412379
NCT04869813
NCT06794853
NCT06811324
Lead Sponsor
Institut Català d'Oncologia
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions